Clinical Trial Phases

In Phase 2 clinical trials, optimizing the dose is one of the most important objectives—balancing efficacy, safety, and pharmacologic parameters. Traditionally, dose selection relied on empirical observation and stepwise escalation. However, with increasing trial complexity and variability among patients, sponsors are adopting statistical simulation models to evaluate multiple dosing strategies and select the most promising dose(s) to carry into Phase 3. This tutorial explains how simulation modeling enhances dose optimization, types of models used, and how regulatory agencies view these approaches.
Click to read the full article.

Phase 2 clinical trials represent a crucial stage in drug development where sponsors assess preliminary efficacy, confirm safety, and determine optimal dosing. Regulatory agencies around the world—FDA (US), EMA (Europe), PMDA (Japan), and CDSCO (India)—each have specific expectations for how these trials should be designed, executed, and reported. Understanding these global requirements early ensures smoother progression to Phase 3 and increases the likelihood of future marketing approval. This tutorial outlines the comparative regulatory landscape for Phase 2 trials across key regions.
Click to read the full article.

After an Investigational New Drug (IND) application is accepted by the U.S. FDA, it must be actively maintained throughout all clinical trial phases. During Phase 2, new data frequently emerge that may require updates to the IND—such as protocol changes, investigator brochures, manufacturing updates, or safety information. This tutorial outlines what constitutes IND maintenance, the types of amendments that apply in Phase 2, submission timelines, and best practices to remain compliant with FDA regulations.
Click to read the full article.